Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia

Giuliana Rizzuto; Matteo Leoncin; Silvia Imbergamo; Daniela Taurino; Maria Caterina Mico; Manuela Tosi; Anna Michelato; Ksenija Buklijas; Orietta Spinelli; Federico Lussana; Federica Lessi; Marco Pizzi; Laura Bonaldi; Gianni Binotto; Alessandro Rambaldi; Carmela Gurrieri

doi:10.1002/ccr3.5212

Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia

Clin Case Rep. 2022 Jan 7;10(1):e05212. doi: 10.1002/ccr3.5212. eCollection 2022 Jan.

Authors

Giuliana Rizzuto^{1

2}, Matteo Leoncin³, Silvia Imbergamo³, Daniela Taurino¹, Maria Caterina Mico¹, Manuela Tosi¹, Anna Michelato¹, Ksenija Buklijas¹, Orietta Spinelli¹, Federico Lussana¹, Federica Lessi³, Marco Pizzi⁴, Laura Bonaldi⁵, Gianni Binotto³, Alessandro Rambaldi^{1

2}, Carmela Gurrieri³

Affiliations

¹ Hematology and Bone Marrow Transplantation Unit Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII Bergamo Italy.
² Department of Oncology-Hematology Universita` degli Studi di Milano Milan Italy.
³ Hematology and Clinical Immunology Unit Universita` degli Studi di Padova Padua Italy.
⁴ Department of Pathology Università degli Studi di Padova Padua Italy.
⁵ Oncological Immunology and Molecular Diagnostic Istituto Oncologico Veneto Padua Italy.

Abstract

The translocation t(8;9)(p22;p24) results in the production of a chimeric PCM1-JAK2 fusion protein leading to the constitutive activation of the Janus Kinase 2 that renders this disease potentially sensitive to ruxolitinib. Here, we report an interesting case of PCM1-JAK2 myeloproliferative neoplasm evolving in myeloid sarcoma and B precursor ALL.

Keywords: PCM1‐JAK2 myeloproliferative neoplasm; acute B‐lymphoblastic leukemia; case report; myeloid sarcoma; ruxolitinib.

Publication types

Case Reports